Member
AuraVax Therapeutics Inc
Industries
biopharma
biotechnology
therapeutics
Nr. of Employees
small (1-50)
AuraVax Therapeutics Inc
AuraVax Therapeutics Inc is currently seeking investment
AuraVax Therapeutics Inc is seeking a seed investment in the range of 1m-5m
Products
Intranasal host-directed therapeutic (STING agonist formulation) for prevention and treatment of respiratory infections
A nanoparticle formulation designed to deliver a STING pathway activator intranasally to boost innate immunity and reduce disease severity and transmission across multiple respiratory pathogens.
Intranasal mucosal vaccine adjuvant (STING agonist nanoparticle)
A liposomal STING agonist intended to enhance mucosal and systemic immune responses when combined with intranasal vaccines, with the goal of improving efficacy and reducing required antigen dose.
Next-generation intranasal host-directed therapeutic (development pipeline)
Ongoing development of subsequent host-directed therapeutic candidates applying the same STING-activation approach for improved efficacy and durability.
Intranasal host-directed therapeutic (STING agonist formulation) for prevention and treatment of respiratory infections
A nanoparticle formulation designed to deliver a STING pathway activator intranasally to boost innate immunity and reduce disease severity and transmission across multiple respiratory pathogens.
Intranasal mucosal vaccine adjuvant (STING agonist nanoparticle)
A liposomal STING agonist intended to enhance mucosal and systemic immune responses when combined with intranasal vaccines, with the goal of improving efficacy and reducing required antigen dose.
Next-generation intranasal host-directed therapeutic (development pipeline)
Ongoing development of subsequent host-directed therapeutic candidates applying the same STING-activation approach for improved efficacy and durability.
Expertise Areas
- Host-directed therapeutics for respiratory disease
- Mucosal immunology and intranasal vaccine adjuvants
- Lipid nanoparticle formulation for airway delivery
- Preclinical respiratory infection and transmission models
Key Technologies
- STING pathway activation (cGAMP delivery)
- Liposomal / lipid nanoparticle delivery
- Intranasal (mucosal) drug delivery
- Mucosal adjuvant platforms